Xencor, Verastem ink new deals; Scynexis' lead drug scores again
→ Xencor has inked a deal with Gilead Sciences. Gilead will have access to Xencor’s Xtend extended half-life and Cytotoxic XmAb Fc technologies for developing and commercializing GS-9722 — currently in Phase I clinical development — and up to three additional anti-HIV antibodies.
→ Verastem Oncology has partnered up with Chugai Pharmaceuticals to obtain worldwide development and commercialization rights to Chugai’s RAF/MEK inhibitor CH5126766 (CKI27) — currently under development for the treatment of KRAS mutant solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.